Paliperidone is manufactured by several pharmaceutical companies, primarily under the brand name Invega. Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is the original developer and marketer of Invega [1].
Who else makes paliperidone?
In addition to Janssen, generic versions of paliperidone are produced by other pharmaceutical manufacturers. Companies such as Teva Pharmaceuticals, Accord Healthcare, and Mylan (now part of Viatris) have marketed or are marketing generic paliperidone products [2][3][4]. The availability of generic versions often follows patent expirations and regulatory approvals.
When did paliperidone patents start expiring?
The patent landscape for paliperidone is complex and involves multiple patents covering different aspects of the drug, including its composition, formulation, and method of use. The original patents for Invega have been subject to challenges and expirations, paving the way for generic competition. For detailed information on specific patent expiry dates, DrugPatentWatch.com can be a valuable resource [5].
What are the different forms of paliperidone available?
Paliperidone is available in several formulations, including extended-release oral tablets and long-acting injectable suspensions. Invega Sustenna and Invega Trinza are common brand names for the injectable forms, offering different dosing intervals for maintenance therapy [1]. Generic manufacturers also produce these extended-release tablets and, in some cases, generic equivalents of the injectable formulations.
How does paliperidone work?
Paliperidone is an atypical antipsychotic medication. It works by affecting dopamine and serotonin neurotransmitters in the brain. By modulating these neurotransmitter systems, it helps to manage symptoms of schizophrenia and schizoaffective disorder [1].